Danaher (NYSE:DHR) was downgraded by research analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a research note issued to investors on Thursday.
DHR has been the subject of several other reports. Wells Fargo & Co began coverage on Danaher in a research report on Tuesday, January 7th. They set an “overweight” rating and a $170.00 price target for the company. Bank of America raised their price target on Danaher from $165.00 to $188.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Credit Suisse Group raised their price target on Danaher from $151.00 to $160.00 and gave the stock an “outperform” rating in a research report on Thursday, December 19th. Zacks Investment Research lowered Danaher from a “hold” rating to a “sell” rating and set a $168.00 price target for the company. in a research report on Tuesday, January 14th. Finally, Cowen restated a “buy” rating and set a $170.00 price target on shares of Danaher in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the stock. Danaher currently has an average rating of “Buy” and a consensus price target of $166.41.
Danaher stock traded up $9.34 during mid-day trading on Thursday, hitting $138.66. The company’s stock had a trading volume of 5,268,591 shares, compared to its average volume of 3,348,842. Danaher has a 1 year low of $119.60 and a 1 year high of $169.19. The stock’s fifty day moving average is $148.72 and its two-hundred day moving average is $147.42. The firm has a market capitalization of $89.92 billion, a PE ratio of 34.24, a price-to-earnings-growth ratio of 2.14 and a beta of 0.96. The company has a current ratio of 5.19, a quick ratio of 4.86 and a debt-to-equity ratio of 0.75.
In related news, SVP William King sold 26,370 shares of Danaher stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $160.23, for a total value of $4,225,265.10. Following the completion of the transaction, the senior vice president now directly owns 22,427 shares in the company, valued at $3,593,478.21. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Donald J. Ehrlich sold 6,014 shares of Danaher stock in a transaction on Monday, February 10th. The shares were sold at an average price of $163.13, for a total value of $981,063.82. Following the completion of the transaction, the director now owns 129,217 shares of the company’s stock, valued at $21,079,169.21. The disclosure for this sale can be found here. Over the last quarter, insiders sold 297,385 shares of company stock valued at $48,153,397. 11.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of DHR. Norges Bank acquired a new stake in Danaher in the fourth quarter valued at $1,095,974,000. Goldman Sachs Group Inc. raised its stake in Danaher by 26.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 5,296,233 shares of the conglomerate’s stock valued at $812,866,000 after buying an additional 1,110,841 shares in the last quarter. Janus Henderson Group PLC raised its stake in Danaher by 12.8% in the fourth quarter. Janus Henderson Group PLC now owns 5,210,644 shares of the conglomerate’s stock valued at $799,731,000 after buying an additional 592,810 shares in the last quarter. Madison Asset Management LLC acquired a new stake in Danaher in the fourth quarter valued at $59,030,000. Finally, Loomis Sayles & Co. L P raised its stake in Danaher by 30.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,651,040 shares of the conglomerate’s stock valued at $253,402,000 after buying an additional 382,882 shares in the last quarter. Institutional investors own 79.72% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: Understanding Analyst Ratings
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.